{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:47:13Z","timestamp":1789555633078,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014427","name":"Dystonia Coalition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014427","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ncl.2020.01.004","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:58:55Z","timestamp":1582937935000},"page":"379-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Treatment of Tardive Dyskinesia"],"prefix":"10.1016","volume":"38","author":[{"given":"Hassaan H.","family":"Bashir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1964.tb05731.x","article-title":"Neurological symptoms in pharmacotherapy of psychoses","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.004_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF00441188","article-title":"Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy","volume":"1","author":"Uhrbrand","year":"1960","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.ncl.2020.01.004_bib3","first-page":"1","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"3","author":"Waln","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PRA.0000000000000224","article-title":"Tardive dyskinesia: a historical perspective","volume":"23","author":"Macaluso","year":"2017","journal-title":"J\u00a0Psychiatr Pract"},{"key":"10.1016\/j.ncl.2020.01.004_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jns.2018.02.005","article-title":"Tardive syndromes","volume":"389","author":"Savitt","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2020.01.004_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2018.02.008","article-title":"The nosology of tardive syndromes","volume":"389","author":"Frei","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.26518","article-title":"The Movement Disorders journal 2016 and onward","volume":"31","author":"Obeso","year":"2016","journal-title":"Mov Disord"},{"issue":"15 Supplement","key":"10.1016\/j.ncl.2020.01.004_bib8","doi-asserted-by":"crossref","first-page":"P4.077","DOI":"10.1212\/WNL.90.15_supplement.P4.077","article-title":"Effect of tardive dyskinesia on quality of life: patient-reported symptom severity is associated with deficits in physical, mental, and social functioning (P4.077)","volume":"90","author":"McEvoy","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.ncl.2020.01.004_bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.clineuro.2011.08.003","article-title":"Status dystonicus in tardive dystonia successfully treated by bilateral deep brain stimulation","volume":"113","author":"Kovacs","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.brs.2016.10.006","article-title":"Fatal status dystonicus in tardive dystonia due to depletion of deep brain stimulation\u2019s pulse generator","volume":"10","author":"Rohani","year":"2017","journal-title":"Brain Stimul"},{"issue":"11","key":"10.1016\/j.ncl.2020.01.004_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/1060028016657553","article-title":"Neuroleptic malignant syndrome","volume":"50","author":"Pileggi","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-200004000-00011","article-title":"Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies","volume":"20","author":"Ballesteros","year":"2000","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.004_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40265-018-0874-x","article-title":"Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors","volume":"78","author":"Niemann","year":"2018","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ncl.2020.01.004_bib14","first-page":"508","article-title":"Prevalence of tardive dyskinesia","volume":"40","author":"Tepper","year":"1979","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4 Suppl","key":"10.1016\/j.ncl.2020.01.004_bib15","first-page":"52S","article-title":"Tardive dyskinesia: prevalence, incidence, and risk factors","volume":"8","author":"Kane","year":"1988","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1176\/ajp.151.6.836","article-title":"Ten-year outcome of tardive dyskinesia","volume":"151","author":"Gardos","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.004_bib17","first-page":"133","article-title":"Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications","volume":"54","author":"Glazer","year":"1993","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.004_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.004_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.004_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry"},{"issue":"10","key":"10.1016\/j.ncl.2020.01.004_bib22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: a study in 16 countries, 2005-2014","volume":"27","author":"H\u00e1lfd\u00e1narson","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.004_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/ps.2008.59.5.507","article-title":"Who are the new users of antipsychotic medications?","volume":"59","author":"Domino","year":"2008","journal-title":"Psychiatr Serv"},{"issue":"Suppl 2","key":"10.1016\/j.ncl.2020.01.004_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bdi.12701","article-title":"Treating depression with adjunctive antipsychotics","volume":"20","author":"Mulder","year":"2018","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.ncl.2020.01.004_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2018.02.007","article-title":"Tardive dyskinesia: epidemiology","volume":"389","author":"D\u2019Abreu","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2020.01.004_bib26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.5334\/tohm.438","article-title":"Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review","volume":"8","author":"D\u2019Abreu","year":"2018","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1016\/j.ncl.2020.01.004_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.parkreldis.2018.11.017","article-title":"Tardive dyskinesia: who gets it and why","volume":"59","author":"Frei","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2020.01.004_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12991-017-0148-0","article-title":"Amisulpride withdrawal dyskinesia: a case report","volume":"16","author":"Lo","year":"2017","journal-title":"Ann Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/ggi.13669","article-title":"Tardive dyskinesia after drug withdrawal in two older adults: clinical features, complications and management","volume":"19","author":"Thomson","year":"2019","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.ncl.2020.01.004_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2016.11.006","article-title":"Life-threatening neuroleptic withdrawal emergent syndrome resembling status dystonicus","volume":"35","author":"Pugin","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"10.1016\/j.ncl.2020.01.004_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40263-013-0079-5","article-title":"Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations","volume":"27","author":"Cerovecki","year":"2013","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib32","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1586\/ern.10.58","article-title":"Tardive dyskinesia and withdrawal emergent syndrome in children","volume":"10","author":"Mejia","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.ncl.2020.01.004_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1017\/S1092852919000488","article-title":"62 predictors of tardive dyskinesia in psychiatric patients taking concomitant antipsychotics","volume":"24","author":"Patterson-Lomba","year":"2019","journal-title":"CNS Spectr"},{"issue":"1\u20133","key":"10.1016\/j.ncl.2020.01.004_bib35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.schres.2014.01.006","article-title":"Chronic and bedtime use of benztropine with antipsychotics: is it necessary?","volume":"153","author":"Wijegunaratne","year":"2014","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","article-title":"Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial","volume":"80","author":"Miller","year":"2005","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib37","article-title":"Anticholinergic medication for antipsychotic-induced tardive dyskinesia","author":"Bergman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ncl.2020.01.004_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2018.02.009","article-title":"Tardive dyskinesia: out of the shadows","volume":"389","author":"Hauser","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"issue":"7","key":"10.1016\/j.ncl.2020.01.004_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40265-016-0568-1","article-title":"Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia","volume":"76","author":"Vijayakumar","year":"2016","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archpsyc.1997.01830130055011","article-title":"Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment","volume":"54","author":"Viguera","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib41","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17r11852","article-title":"Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis","volume":"79","author":"Mentzel","year":"2018","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib42","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/0706743719828968","article-title":"Treatment recommendations for tardive dyskinesia","volume":"64","author":"Ricciardi","year":"2019","journal-title":"Can J Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1212\/CPJ.0000000000000342","article-title":"Pimavanserin: a novel therapeutic option for Parkinson disease psychosis","volume":"7","author":"Hawkins","year":"2017","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.ncl.2020.01.004_bib44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.schres.2019.02.018","article-title":"Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist","volume":"208","author":"Nasrallah","year":"2019","journal-title":"Schizophr Res"},{"key":"10.1016\/j.ncl.2020.01.004_bib45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5334\/tohm.199","article-title":"Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic","volume":"4","author":"Zutshi","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.004_bib46","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1085\/jgp.201711980","article-title":"The ins and outs of vesicular monoamine transporters","volume":"150","author":"Yaffe","year":"2018","journal-title":"J\u00a0Gen Physiol"},{"issue":"18","key":"10.1016\/j.ncl.2020.01.004_bib47","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"10.1016\/j.ncl.2020.01.004_bib48","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","article-title":"Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature","volume":"34","author":"Chen","year":"2012","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/WNF.0000000000000326","article-title":"Real-world experience with VMAT2 inhibitors","volume":"42","author":"Niemann","year":"2019","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","article-title":"Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"10.1016\/j.ncl.2020.01.004_bib51","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol","volume":"156","author":"Ondo","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib52","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.004_bib54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.01.004_bib55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib56","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/mds.25278","article-title":"Analysis of CYP2D6 genotype and response to tetrabenazine","volume":"28","author":"Mehanna","year":"2013","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.004_bib57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd.2016.63","article-title":"Deuterated drugs draw heavier backing","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ncl.2020.01.004_bib58","author":"Teva Pharmaceuticals USA Inc"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib59","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with huntington disease: a randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ncl.2020.01.004_bib60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14737175.2018.1500178","article-title":"Deutetrabenazine for the treatment of Huntington\u2019s chorea","volume":"18","author":"Bashir","year":"2018","journal-title":"Expert Rev Neurother"},{"issue":"21","key":"10.1016\/j.ncl.2020.01.004_bib61","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ncl.2020.01.004_bib62","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"10.1016\/j.ncl.2020.01.004_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13030","article-title":"Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"71","author":"Citrome","year":"2017","journal-title":"Int J Clin Pract"},{"issue":"12","key":"10.1016\/j.ncl.2020.01.004_bib64","first-page":"1317","article-title":"Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia","volume":"90","author":"Fernandez","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.004_bib65","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.ejmech.2011.02.046","article-title":"Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors","volume":"46","author":"Yao","year":"2011","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib66","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543784.2015.1029573","article-title":"Valbenazine granted breakthrough drug status for treating tardive dyskinesia","volume":"24","author":"M\u00fcller","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"10.1016\/j.ncl.2020.01.004_bib67","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"30","author":"O\u2019Brien","year":"2015","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.004_bib68","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.1016\/j.ncl.2020.01.004_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12964","article-title":"Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"71","author":"Citrome","year":"2017","journal-title":"Int J Clin Pract"},{"issue":"9","key":"10.1016\/j.ncl.2020.01.004_bib70","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4088\/JCP.17m11777","article-title":"The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study","volume":"78","author":"Factor","year":"2017","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1017\/S1092852919000579","article-title":"77 long-term valbenazine treatment in patients with schizophrenia\/schizoaffective disorder or mood disorder and tardive dyskinesia","volume":"24","author":"Lindenmayer","year":"2019","journal-title":"CNS Spectr"},{"issue":"10","key":"10.1016\/j.ncl.2020.01.004_bib72","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.25107","article-title":"Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis","volume":"27","author":"Teo","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.01.004_bib73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2018.02.014","article-title":"Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia","volume":"389","author":"Lin","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.004_bib74","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","article-title":"Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy","volume":"147","author":"Thaker","year":"1990","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib75","first-page":"729","article-title":"Diazepam-induced changes in tardive dyskinesia: suggestions for a new conceptual model","volume":"17","author":"Singh","year":"1982","journal-title":"Biol Psychiatry"},{"issue":"7\u20138","key":"10.1016\/j.ncl.2020.01.004_bib76","first-page":"523","article-title":"Diazepam in tardive dyskinesia","volume":"17","author":"Weber","year":"1983","journal-title":"Drug Intell Clin Pharm"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib77","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00004714-198804000-00028","article-title":"The effect of benzodiazepines on tardive dyskinesia symptoms","volume":"8","author":"Csernansky","year":"1988","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.ncl.2020.01.004_bib78","first-page":"673","article-title":"Tardive dyskinesia successfully treated with alprazolam","volume":"82","author":"Jordan","year":"1990","journal-title":"J\u00a0Natl Med Assoc"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.fitote.2008.05.007","article-title":"Biology and chemistry of Ginkgo biloba","volume":"79","author":"Singh","year":"2008","journal-title":"Fitoterapia"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.004_bib80","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4088\/JCP.09m05125yel","article-title":"Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Zhang","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.ncl.2020.01.004_bib81","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40265-016-0566-3","article-title":"Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia","volume":"76","author":"Vijayakumar","year":"2016","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ncl.2020.01.004_bib82","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM197103252841216","article-title":"Amantadine for dyskinesia tarda","volume":"284","author":"Vale","year":"1971","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.ncl.2020.01.004_bib83","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJM197110072851516","article-title":"Amantadine hydrochloride treatment of tardive dyskinesia","volume":"285","author":"Decker","year":"1971","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.ncl.2020.01.004_bib84","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJM197204062861424","article-title":"Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism","volume":"286","author":"Janowsky","year":"1972","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","article-title":"A\u00a0controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia","volume":"17","author":"Angus","year":"1997","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"33","author":"Pappa","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"10.1016\/j.ncl.2020.01.004_bib87","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.pnpbp.2004.05.045","article-title":"Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials","volume":"28","author":"Tammenmaa","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.004_bib88","article-title":"Cholinergic medication for antipsychotic-induced tardive dyskinesia","author":"Tammenmaa-Aho","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.004_bib89","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.870010305","article-title":"Natural history and treatment of tardive dystonia","volume":"1","author":"Kang","year":"1986","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.004_bib90","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00004714-199906000-00017","article-title":"Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (the Pisa syndrome)","volume":"19","author":"Suzuki","year":"1999","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib91","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1212\/WNL.36.2.160","article-title":"Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl","volume":"36","author":"Burke","year":"1986","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.004_bib92","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/2045125314553611","article-title":"Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia","volume":"4","author":"Desmarais","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"issue":"9","key":"10.1016\/j.ncl.2020.01.004_bib93","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.ncl.2020.01.004_bib94","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/mds.25480","article-title":"Zolpidem improves tardive dyskinesia and akathisia","volume":"28","author":"Waln","year":"2013","journal-title":"Mov Disord"},{"issue":"1 Epilepsy","key":"10.1016\/j.ncl.2020.01.004_bib95","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1212\/CON.0000000000000289","article-title":"Antiepileptic drugs","volume":"22","author":"Abou-Khalil","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"8","key":"10.1016\/j.ncl.2020.01.004_bib96","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/mds.20835","article-title":"Levetiracetam in tardive dyskinesia: an open label study","volume":"21","author":"Konitsiotis","year":"2006","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib97","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.jcp.0000203823.60603.80","article-title":"Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series","volume":"26","author":"Bona","year":"2006","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.004_bib98","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v69n0405","article-title":"Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Woods","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.ncl.2020.01.004_bib99","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ajp.2013.12.016","article-title":"Management of tardive syndromes with clozapine: a case series","volume":"8","author":"Grover","year":"2014","journal-title":"Asian J Psychiatr"},{"issue":"9","key":"10.1016\/j.ncl.2020.01.004_bib100","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.09m05155yel","article-title":"A\u00a0randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia","volume":"71","author":"Chan","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.004_bib101","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41582-018-0128-2","article-title":"Deep brain stimulation: current challenges and future directions","volume":"15","author":"Lozano","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ncl.2020.01.004_bib102","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jns.2018.02.013","article-title":"Deep brain stimulation for tardive syndromes: systematic review and meta-analysis","volume":"389","author":"Macerollo","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"issue":"7","key":"10.1016\/j.ncl.2020.01.004_bib103","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0000000000002370","article-title":"Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia","volume":"86","author":"Pouclet-Courtemanche","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1212\/WNL.0b013e3181aaea01","article-title":"Long-term effects of pallidal deep brain stimulation in tardive dystonia","volume":"73","author":"Gruber","year":"2009","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2020.01.004_bib105","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4103\/0366-6999.181977","article-title":"Long-term effects of subthalamic nucleus deep brain stimulation in tardive dystonia","volume":"129","author":"Meng","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ncl.2020.01.004_bib106","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2017.05.010","article-title":"Long-term follow-up of bilateral subthalamic deep brain stimulation for refractory tardive dystonia","volume":"41","author":"Deng","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"10.1016\/j.ncl.2020.01.004_bib107","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: state of the art","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.004_bib108","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.pnpbp.2007.09.010","article-title":"Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature","volume":"32","author":"Hennings","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"15","key":"10.1016\/j.ncl.2020.01.004_bib109","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/mds.22549","article-title":"Botulinum toxin in the treatment of lingual movement disorders","volume":"24","author":"Kasravi","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.01.004_bib110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.toxicon.2017.09.003","article-title":"An update on new and unique uses of botulinum toxin in movement disorders","volume":"147","author":"Jankovic","year":"2018","journal-title":"Toxicon"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib111","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.pnpbp.2007.10.004","article-title":"Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study","volume":"32","author":"Slotema","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.004_bib112","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/09540261.2017.1309362","article-title":"Key updates in the clinical application of electroconvulsive therapy","volume":"29","author":"Weiner","year":"2017","journal-title":"Int Rev Psychiatry"},{"issue":"7","key":"10.1016\/j.ncl.2020.01.004_bib113","first-page":"265","article-title":"ECT and tardive dyskinesia: two cases and a review","volume":"44","author":"Chacko","year":"1983","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.004_bib114","first-page":"262","article-title":"Successful electroconvulsive treatment of depression associated with a marked reduction in the symptoms of tardive dyskinesia","volume":"20","author":"Nobuhara","year":"2004","journal-title":"J\u00a0ECT"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.004_bib115","first-page":"e52","article-title":"Electroconvulsive therapy for a patient with persistent tardive dyskinesia","volume":"29","author":"Peng","year":"2013","journal-title":"J\u00a0ECT"},{"key":"10.1016\/j.ncl.2020.01.004_bib116","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/NDT.S62490","article-title":"The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study","volume":"10","author":"Yasui-Furukori","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"10.1016\/j.ncl.2020.01.004_bib117","first-page":"865","article-title":"Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems","volume":"18","author":"Holcomb","year":"1983","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.004_bib118","first-page":"92","article-title":"Electroconvulsive therapy in a patient with mania, parkinsonism, and tardive dyskinesia","volume":"4","author":"Roth","year":"1988","journal-title":"Convuls Ther"},{"issue":"10","key":"10.1016\/j.ncl.2020.01.004_bib119","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1176\/ajp.135.10.1235","article-title":"A\u00a0single-blind study of ECT in patients with tardive dyskinesia","volume":"135","author":"Asnis","year":"1978","journal-title":"Am J Psychiatry"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:18:23Z","timestamp":1760005103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861920300049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0733861920300049"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2020.01.004","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Tardive Dyskinesia","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2020.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}